Scrip Dividend Declaration & Additional Listing

Source: RNS
RNS Number : 3693V
Assura PLC
08 July 2024
 

8 July 2024

Assura plc

Scrip Dividend Declaration & Additional Listing

Assura plc ("Assura" or "the Company"), the specialist healthcare property investor and developer, today announces that 2,198,592 new Ordinary Shares ("the New Shares") have been issued pursuant to the Scrip Dividend Scheme (945,664) and relating to employee incentive schemes (1,252,928).

Application has therefore been made for the admission of the New Shares to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). The New Shares will rank pari passu with the Company's existing ordinary shares and Admission is expected to occur at 8.00am on 10 July 2024.

Following the allotment of the New Shares, it is expected that the total number of shares in issue will be 2,991,952,982 (none of which will be held in treasury) and that, accordingly, the total number of voting rights of the Company will be 2,991,652,982.

Scrip dividend scheme

Pursuant to its Scrip Dividend Scheme and in response to the scrip dividend alternative for the quarterly interim dividend payable on 10 July 2024 (the "Scrip Dividend Alternative"), elections were received in respect of 1.7 per cent. of the Company's ordinary shares in issue as at the record date of 7 June 2024.

Electing shareholders will receive ordinary shares in the Company ("Shares") in lieu of cash in respect of this dividend and, accordingly 945,664 Shares (the "New Shares") will be issued by the Company to such shareholders.

Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).

This interim dividend is 100% Property Income Distribution ("PID"). Forms to register for gross PIDs (on future interim dividends) are available on the Company's website. Please click here for PID Forms.

Employee incentive schemes

A further 1,252,928 new Ordinary Shares have been issued to the Assura plc Employee Benefit Trust in order to satisfy the awards pursuant to the 2021 Performance Share Plan, restricted share awards pursuant to the Performance Share Plan and a free award to all eligible employees under the Share Incentive Plan.

- ENDS -

For more information, please contact:

 

Assura plc
David Purcell, Investor Relations Director

Tel: 0161 515 2043
Email: Investor@assura.co.uk

FGS Global
Gordon Simpson

Tel: 0207 251 3801
Email: Assura@fgsglobal.com

Notes to Editors

Assura plc is the UK's leading specialist healthcare property investor and developer. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).

Further information is available at www.assuraplc.com

Assura plc LEI code: 21380026T19N2Y52XF72

*EPRA is a registered trademark of the European Public Real Estate Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVMZGGNFKMGDZM